Vical Incorporated (VICL)

Oncology Corporate Profile

Stock Performance

2.7300
0.0700

HQ Location

10390 Pacific Center Court
San Diego, CA 92121

Company Description

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. It develops DNA-based vaccines and therapeutics for the prevention/treatment of infectious diseases, cardiovascular diseases, and cancer, including Allovectin-7 cancer immunotherapeutic, a Phase III clinical trial product for the treatment of metastatic melanoma.

Website: http://www.vical.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
IL-2/EPimmunotherapy1st line metastatic MelanomaI

View additional information on product candidates here »

Source: http://www.vical.com

Recent News Headlines

Less Than Half Of Cervical Cancer Patients Receive Standard-Of-Care Treatment

11/1/2016 11:11 am

(UCCC/Colorado Cancer Blogs) Oct 31, 2016 - Standard-of-care treatment for locally advanced cervical cancer includes radiation, chemotherapy and brachytherapy (in which radiation is implanted internally). A University of Colorado Cancer Center study published in the journal Gynecologic Oncology shows that only 44 percent of patients in a large, national sample received all three components of this accepted, best treatment.

Cervical Cancer Screening Could Be Less Frequent, Start Later

10/18/2016 11:29 am

(Harvard Gazette) Oct 17, 2016 - Women may only need cervical cancer screening every five to 10 years — instead of every three years, as currently recommended — and may be able to start screenings later in life, according to a new study from the Harvard T.H. Chan School of Public Health.

ASCO Issues New Guideline for Global Cervical Cancer Screening

10/13/2016 11:07 am

(Medscape Medical News) Oct 12, 2016 - A new global guideline on screening for cervical cancer, which provides evidence-based recommendations for screening, follow-up, and treatment for high-risk lesions, has been released by the American Society of Clinical Oncology (ASCO).

ASCO Issues Global Recommendations to Increase Cervical Cancer Screening

10/13/2016 06:45 am

(ASCO) Oct 12, 2016 - The American Society of Clinical Oncology (ASCO) today issued a new global guideline on screening for cervical cancer, one of the leading causes of cancer related death among women worldwide.

Less Regular Cervical Screening Could Benefit Women, Study Suggests

10/6/2016 11:16 am

(Cancer Research UK/Press Association) Oct 5, 2016 - Extending the gap between cervical screening tests from five to 10 years is safe for women who test negative for the human papillomavirus (HPV), according to Dutch research.

Need to Revisit Cervical Cancer Screening Guidelines: JAMA Oncology Study

9/30/2016 11:44 am

(AJMC) Sept 29, 2016 - Untreated human papillomavirus (HPV) infection has been identified as a leading cause of developing cervical intraepithelial neoplasia (CIN), which can lead to invasive cervical cancer. While several studies have documented the success of HPV vaccination in preventing the viral infection and development of low-grade and high-grade CIN, the impact of subsequent reduced screening rates have not been examined.

Cervical and Endometrial Cancer Patients Report Fewer Side Effects And Better Quality Of Life With IMRT

9/27/2016 11:13 am

(ASTRO Annual Meeting) Sept 26, 2016 - Patients with cervical and endometrial cancer have fewer gastrointestinal and genitourinary side effects and experience better quality of life when treated with intensity-modulated radiation therapy (IMRT) than with conventional radiation therapy (RT), according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO).

HIV Doubles Risk for Cervical Cancer Death in Africa

9/2/2016 09:52 am

(Medscape Medical News) Sept 1, 2016 - Women with HIV infection have a higher risk of developing cervical cancer, but the presence of HIV also significantly increases the risk of dying of the cancer, according to findings from a new study of African patients.

Advaxis’ AXAL Receives Fast Track Designation by the FDA as Adjuvant Therapy for High-Risk Locally Advanced Cervical Cancer Patients

7/21/2016 10:49 am

(Yahoo! Finance) July 21, 2016 - Advaxis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated the Company’s lead immunotherapy candidate, axalimogene filolisbac (AXAL), as a Fast Track product for adjuvant therapy for high-risk locally advanced cervical cancer patients.

China Approves Use Of GSK Vaccine Cervarix For Cervical Cancer

7/18/2016 11:08 am

(Reuters) July 18, 2016 - Drugmaker GlaxoSmithKline Plc said on Monday the China Food and Drug Administration (CFDA) has approved its human papillomavirus (HPV) vaccine, Cervarix, for use in the country to help women fight cervical cancer.

Roche Receives FDA Approval for Use of SurePath Preservative Fluid with Cobas HPV Test for Cervical Cancer Screening

7/8/2016 11:12 am

(Yahoo! Finance) July 8, 2016 - Roche HPV test is first to be approved for use with the SurePath Preservative Fluid gynecologic cell collection medium commonly used for Pap tests.

Cervical Cancer Screening In England To Use ‘More Accurate’ Viral DNA Test

7/8/2016 11:09 am

(Cancer Research UK/Press Association) June 6, 2016 - The NHS cervical screening programme in England will switch to first testing women for signs of infection with the virus that causes cervical cancer, rather than initially looking for abnormal cells.

Routine Screenings Prevent Cervical Cancer in Elderly Women

7/8/2016 11:08 am

(University of Illinois/Illinois News Bureau) July 7, 2016 - A new study from the University of Illinois confirms a link between routine Pap smear screenings and a lower risk of developing cervical cancer in women over age 65. However, most American health guidelines discourage women in that age range from receiving screenings unless they have pre-existing risk factors.

FDA Grants Special Protocol Assessment to Advaxis’ Phase 3 Study of AXAL in Patients with Cervical Cancer

7/6/2016 12:13 pm

(P&T Community) July 6, 2016 - Advaxis, Inc., a clinical stage biotechnology company developing cancer immunotherapies, today announced that it reached an agreement with the U.S. Food and Drug Administration (FDA), under the Special Protocol Assessment (SPA) process, for the Phase 3 AIM2CERV trial evaluating the Company’s lead Lm immunotherapy candidate, axalimogene filolisbac (AXAL), in patients with high-risk, locally advanced cervical cancer (HRLACC).

HPV Vaccination Reduces Cervical Abnormalities In Young Women, Study Finds

7/5/2016 11:07 am

(CBC News/The Canadian Press) July 5, 2016 - Young women immunized against human papilloma virus were significantly less likely to have potentially cancerous cervical abnormalities compared to those who didn't receive the HPV vaccine, a study of more than 10,000 subjects has found.

UCLA Researchers Identify Protein That Could Prevent Tumor Growth In Cervical Cancer

5/31/2016 11:37 am

(UCLA) May 31, 2016 - Scientists found that a protein called cystatin E/M can inhibit cellular inflammation, which is a major contributor to the growth of the disease; the discovery could lead to the development of new treatments.

Cervical Cancer Guide Backs Chemoradiation

5/25/2016 11:21 am

(MedPage Today) May 24, 2016 - Concurrent chemoradiation represents standard of care for stage IB to IVA invasive cervical cancer, as available resources permit, according to a new clinical guideline from the American Society of Clinical Oncology (ASCO).

Exercise May Reduce the Risk of Cervical Cancer

5/11/2016 11:40 am

(RPCI) May 10, 2016 - Even 30 minutes of exercise per week has the potential to significantly reduce a woman’s risk of developing cervical cancer, according to a study from scientists at Roswell Park Cancer Institute (RPCI).

New HPV Vaccine Could Curb Cervical Cancers And Health Costs If Adopted Widely

4/19/2016 02:16 pm

(Yale News) Apr 18, 2016 - A Yale-led study finds that a new vaccine for human papillomavirus (HPV) would significantly reduce both cervical cancer incidence and healthcare costs if states coordinated policies to improve coverage.

HPV: Cervical Peeling As A Treatment For Precancerous Conditions

3/30/2016 11:53 am

(MedUni Vienna [Austria]) Mar 30, 2016 - Researchers at the Comprehensive Cancer Center (CCC) of MedUni Vienna and Vienna General Hospital have developed a new treatment for the pre-stages of cervical cancer, caused by human papilloma virus (HPV) infection.

Dosing Begins in High Dose Expansion Cohort in Phase 2 Study of Axalimogene Filolisbac in Patients With Recurrent Cervical Cancer

3/7/2016 11:59 am

(TheStreet) Mar 7, 2016 - Advaxis, Inc. today announced dose administration for the first patient in the expansion phase of an ongoing Phase 2 clinical trial of its lead Lm immunotherapy candidate, axalimogene filolisbac (AXAL), in patients with persistent or recurrent metastatic (squamous or non-squamous cell) carcinoma of the cervix (PRmCC).

Navidea Biopharmaceuticals Enrolls First Patient in Cervical Cancer Study of Lymphoseek®

2/11/2016 11:43 am

(TheStreet) Feb 11, 2016 - Navidea Biopharmaceuticals, Inc., today announced that the first patient has been enrolled in a clinical study evaluating Lymphoseek® (technetium Tc 99m tilmanocept) injection in women with known cervical cancer.

Lion Biotechnologies Announces Allowance of IND Application to Begin Clinical Trials in Cervical, Head and Neck Cancers

2/1/2016 12:54 pm

(StreetInsider) Feb 1, 2016 - Lion Biotechnologies, Inc., a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that the US Food and Drug Administration (FDA) has allowed its investigational new drug (IND) application to conduct clinical trials of LN-145 in the treatment of cervical cancer, and head and neck squamous cell carcinoma (HNSCC).

NHS Cancer Patients Gain Access To Four New Therapies

1/27/2016 07:02 am

(PharmaTimes [UK]) Jan 27, 2016 - The National Institute for Health and Care Excellence has issued final recommendations endorsing National Health Service use of new therapies for ovarian cancer, multiple myeloma and prostate cancer, but rejecting one for gastric cancer.

Five Factors Identify Subset of Patients With Advanced Cervical Cancer Who May Not Benefit From Bevacizumab Treatment

12/15/2015 10:48 am

(AACR) Dec 15, 2015 - Patients with advanced cervical cancer who were at intermediate and high risk of poor outcome, as assessed by the Moore criteria, gained survival benefit from having bevacizumab added to their chemotherapy regimen while those at low risk of poor outcome did not, according to results of a major objective of the phase III NRG Oncology-Gynecologic Oncology Group protocol 240 (GOG 240) clinical trial published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

Guided Therapeutics and FDA Review Team Agree on Path Forward for LuViva® Advanced Cervical Scan PMA Application

12/2/2015 12:01 pm

(Yahoo! Finance) Dec 2, 2015 - Guided Therapeutics, Inc., the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today it believes it has reached a general agreement with the U.S. Food and Drug Administration (FDA) on a plan for submitting an approvable application for the LuViva® Advanced Cervical Scan.

How to Study 1 Million Patients' Medical Charts

9/18/2015 12:01 pm

(Scientific American) Sept 18, 2015 - A rough draft has been released for an effort to offer better health care tailored to each individual in the era of whole-genome analysis.

ASCO Supports NCI Bypass Budget for Fiscal Year 2017

9/18/2015 12:00 pm

(ASCO) Sept 17, 2015 - "ASCO strongly supports the National Cancer Institute's (NCI) proposed budget for the 2017 fiscal year."

ASCO Reviewing HHS Proposal to Common Rule

9/18/2015 12:00 pm

(ASCO in Action) Sept 18, 2015 - The U.S. Department of Health and Human Services (HHS), along with 15 other government agencies, recently announced proposed revisions to the Common Rule, regulations that govern the protection of human subjects in research.

End Needless — and Expensive — Treatments for Cancer

9/18/2015 12:00 pm

(American Enterprise Institute/Inside Sources) Sept 16, 2015 - In a recent, much noted article, more than 100 prominent oncologists complained that the high cost of new cancer drugs — in excess of $100,000 per treatment — makes them unaffordable for patients.

Pancreatic Cancer Action Network and American Association for Cancer Research Invite Applications for 2016 Research Grants

9/18/2015 12:00 pm

(AACR) Sept 18, 2015 - The American Association for Cancer Research (AACR) and the Pancreatic Cancer Action Network are pleased to announce the opening of the 2016 Research Grants Program to support early-career investigators to focus on pancreatic cancer.

Hospitalization Rates in Chemo Trials May Be Misleading

9/18/2015 11:05 am

(Fox News/Reuters) Sept 17, 2015 - Cancer patients need to be prepared for serious side effects from chemotherapy, and hospitalization is one that happens much more often in the real world than in drug trials, according to a new study.

Infinity Expands Pipeline with Addition of IPI-549, an Immuno-Oncology Development Candidate for the Treatment of Solid Tumors

9/18/2015 11:05 am

(MarketWatch) Sept 18, 2015 - Infinity Pharmaceuticals, Inc. today announced the expansion of its pipeline with the addition of IPI-549, an orally administered immuno-oncology development candidate that selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma), for the treatment of solid tumors.

Telepharmacy Shows Its Worth in Cancer Setting

9/18/2015 11:05 am

(Pharmacy Practice News) September 2015 - In the early months of 2011, Smilow Cancer Hospital at Yale-New Haven in Connecticut, was facing a big challenge.

Information Blocking Undermining ASCO's CancerLinQ Initiative

9/18/2015 11:05 am

(Medscape Medical News) Sept 17, 2015 - CancerLinQ, the ambitious data-sharing initiative announced by the American Society of Clinical Oncology (ASCO) in 2013 to improve the quality of cancer care to all patients in the United States, is on the verge of being undermined as barriers to sharing information continue to block the ability of oncologists to mine data contained in different electronic health records (EHR) across the country, ASCO members are reporting.

ICD-10 Implementation: Last Minute Details

9/18/2015 11:05 am

(ASCO in Action) Sept 17, 2015 - There are only two weeks left until the implementation of ICD-10, which will fully replace the ICD-9 procedure coding system on October 1.

Vismodegib Plus Radiotherapy Promising in Recurrent Advanced BCC

9/18/2015 11:03 am

(Medscape Medical News) Sept 17, 2015 - A case report of two patients suggests potential synergy between concurrent vismodegib (Erivedge, Genentech) and radiotherapy for recurrent advanced basal cell carcinoma (BCC).

Tips for Managing CV Toxicity With TKIs in Leukemia Patients

9/18/2015 11:03 am

(Medscape Medical News) Sept 17, 2015 - Practical recommendations for managing cardiovascular risk in patients with chronic myeloid leukemia (CML) who are taking tyrosine kinase inhibitors (TKIs) are outlined in a review published online September 14 in the Journal of Clinical Oncology.

Reality Check: Cancer Experts Discuss Hurdles Facing CAR-T Therapy

9/18/2015 11:03 am

(Xconomy) Sept 18, 2015 - There's a lot of excitement these days about a type of cellular immunotherapy known as CAR-T, a method of modifying peoples' immune cells to fight cancer.

Heron Therapeutics Announces FDA Acceptance of New Drug Application for SUSTOL®

9/18/2015 11:03 am

(MarketWatch) Sept 18, 2915 - FDA assigns PDUFA goal date of January 17, 2016; SUSTOL has potential to be first 5-HT3 antagonist approved for delayed nausea and vomiting associated with highly emetogenic chemotherapy.

Bristol-Myers Squibb Foundation Awards Additional Grants to Promote Cervical Cancer Screenings and Services for Women Living with HIV in Tanzania

9/18/2015 11:03 am

(Bristol-Myers) Sept 18, 2015 - The Bristol-Myers Squibb Foundation today announced four new grants awarded through its landmark Secure the Future initiative that will strengthen community-based services addressing cervical cancer in Tanzania, where women living with HIV are more likely to die from cervical cancer than AIDS.

Vical Announces Restructuring and Staff Reduction

8/23/2013 02:03 pm

(Yahoo! Finance) Aug 22, 2013 - Vical Incorporated today announced a restructuring to conserve capital, including a staff reduction of 47 employees, approximately 39% of the company's total workforce.

Vical Drops Cancer Therapy After Trial Failure, Shares Plunge

8/12/2013 12:03 pm

(Reuters) Aug 12, 2013 - Vical Inc said it would stop developing its most advanced product, cancer therapy Allovectin, after a late-stage trial failed to show that the treatment was significantly better than chemotherapy.

Vical to Present at JMP Securities Healthcare Conference

7/5/2012 10:03 am

[GlobeNewswire] - SAN DIEGO -- Vical Incorporated today announced that the company will provide an overview of its technologies, development programs, and outlook on Thursday, July 12, at 3:30 p.m. ET at the JMP Securities ...

Vical to Present at Wells Fargo Securities Healthcare Conference

6/13/2012 10:03 am

[GlobeNewswire] - SAN DIEGO -- Vical Incorporated today announced that the company will provide an overview of its technologies, development programs, and outlook on Wednesday, June 20, at 12:40 p.m. ET at the Wells Fargo ...

Vical Announces Publication of Herpes Simplex Vaccine Mouse Study Data

5/22/2012 10:03 am

[GlobeNewswire] - SAN DIEGO -- Vical Incorporated today announced the online publication of a new article1 in The Journal of General Virology detailing results from the company's completed mouse studies with the company's ...